Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

Taysha Gene Therapies announced that, on January 2, 2024, Taysha’s Board of Directors granted Meredith Schultz, M.D., M.S., an option to purchase 257,700 shares of the Company’s common stock in connection with her employment as Taysha’s new Senior Vice President, Clinical Development and Medical Affairs. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to Ms. Schultz entering into employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $1.71 per share, which is equal to the closing price of Taysha’s common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee’s continued service to Taysha on each vesting date.